TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04816214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib was available as a film-coated tablet for oral use, with a strength of either 150 mg or 200 mg. The initial dose of the combination therapy consisted of capmatinib 400 mg administered orally twice daily (b.i.d).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib was available as a film-coated tablet for oral use, with a strength of either 150 mg or 200 mg. The initial dose of the combination therapy consisted of capmatinib 400 mg administered orally twice daily (b.i.d).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib was available as a tablet for oral use, with a strength of either 80 mg or 40 mg. The initial dose of the combination therapy consisted of osimertinib 80 mg administered orally once per day (q.d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib was available as a tablet for oral use, with a strength of either 80 mg or 40 mg. The initial dose of the combination therapy consisted of osimertinib 80 mg administered orally once per day (q.d)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed concentrate for solution for intravenous use was to be administered intravenously. The procurement of pemetrexed was to be done locally, following local practices and regulations.
Study: NCT05383157

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual pain care as delivered in the clinic involving pain assessment and prescription of analgesics.
Study: NCT04816214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin concentrate for solution for intravenous use was to beadministered intravenously during the study. The procurement of cisplatin was to be done locally, following local practices and regulations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin concentrate for solution for intravenous use was to be administered intravenously during the study. The procurement of carboplatin was to be done locally, following local practices and regulations.
Study: NCT05206149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal glugagon
Description: Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Intranasal placebo (represented by isotonic saline solution) is administered.
Study: NCT05944679

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: No Xray
Description: Just one Xray 12 months after the intervention

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Xray
Description: Xray at 1, 3, 6 and 12 months after intervention
Study: NCT05130190

Intervention type: DEVICE
Group type: OTHER
Intervention: RF Treatment
Description: ProVu treatment probe will be energized and RF energy delivered in a pre-programmed, controlled method based on the predetermined size of the affected tissue.
Study: NCT06100250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and specimen self-collection
Description: Participants will be asked to attend a pre-test live AV conferencing session, collect and return a urine sample, a throat swab, a rectal swab, and a blood sample for bacterial STI testing, and attend a post-test live AV conferencing session.
Study: NCT04832373

Intervention type: DEVICE
Group type: OTHER
Intervention: Interaction with humanoid robot
Description: A humanoid robot will be installed for 30 days in children. It has a touchscreen tablet, allowing manual interaction complementing the voice interaction. The robot speaks, hears, and has facial and voice identification.
Study: NCT05053984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Echoguided Neuromodulation
Description: Once the nerve is located, a needle is introduced in the vicinity of the nerve and is stimulated using an electrical current with a frequency of 10 Hz, with a pulse width of 250 µs and a tolerable intensity causing a visible muscle contraction for 1.5 minutes.
Study: NCT05714488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blue halo coil catheter
Description: device inserted with coil at the bladder and straight arm in the prostatic urethra proximal to the external sphincter
Study: NCT05069922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Fresh Frozen Plasma

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Fresh Frozen Plasma
Study: NCT04710251

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Speedometer
Description: We will measure and monitor the withdrawal time of colonoscopy with a speedometer.
Study: NCT05902208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiviral treatment with conventional non-surgical treatment
Description: Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered during 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with conventional non-surgical treatment
Description: Placebo of valaciclovir (same composition, without active substance) will be added to the conventional non-surgical treatment of generalized periodontitis. One gram a day will be administered during 28 days.
Study: NCT05882227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video
Description: The patients will receive the discharge information through the visualization of a video with discharge information extracted from the optimized hip prosthesis recovery program document; information for patients, relatives or caregivers. The video will consist of two parts: a first part where it will be explained what will happen in the next hours in the unit, the documentation that will be delivered at discharge and the pharmacological treatment. The second part will consist of a video explaining wound care at discharge, discharge recommendations, symptoms that may appear after surgery and alarm symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional information
Description: Patients will receive the information at discharge by means of the document entitled Optimized Hip Replacement Recovery Program; information for patients, relatives or caregivers, which will act as a control group.
Study: NCT05090046

Intervention type: OTHER
Intervention: Trauma exposure
Description: Exposure to the Canterbury earthquake sequence and other relevant psychological trauma
Study: NCT06037148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DM-101PX
Description: subcutaneous injection of DM-101PX

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DM-101PX
Description: subcutaneous injection of DM-101PX

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DM-101PX
Description: subcutaneous injection of DM-101PX
Study: NCT05466227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of Modified Valsalva maneuvre
Description: Modified Valsalva maneuvre:~* Patient is attached to 12-lead ECG monitoring~* The patient sits in an upright position and performs forced expiration for 15 seconds by blowing on a 10 mL syringe~* Patient's legs are elevated (45°) for 15 seconds~* Afterwards, the patient is placed back in an upright position~* If not efficient, this maneuver can be repeated up to two times
Study: NCT04976192

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TEV-45779
Description: TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TEV-45779
Description: TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TEV-45779
Description: TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TEV-45779
Description: TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TEV-45779
Description: TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TEV-45779
Description: TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: XOLAIR® Injection
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: XOLAIR® Injection
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: XOLAIR® Injection
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: XOLAIR® Injection
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: XOLAIR® Injection
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: XOLAIR® Injection
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
Study: NCT06143475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FPS group
Description: Vibration frequency ranged from 0 to 100 Hz. There were 3 modes of FPS application during rehabilitation course. 1) anti-spasticity mode (FV): the stimulators were placed in the middle of the muscles of the affected limb (i.e. unilaterally); 2) bilateral mode of proprioceptive facilitation; and 3) the unilateral mode of the proprioceptive facilitation.~The 2 first sessions were realized with bilateral FPS stimulations plus the anti-spasticity FV mode to reduce the level of hypertonia. Then for 6 consecutive sessions unilateral FPS stimulations of the affected sides imitating the drawing of a straight lines (horizontal, vertical, diagonal), preparing for writing (drawing a circle, triangle, square, spiral) were realized. At last, the 4 remaining FPS sessions were realized unilaterally imitating and promoting the realization of everyday life activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy group
Description: Patients received sessions of traditional physical therapy: individual therapy sessions including exercises to strengthen muscles, stretching, reflex exercises for large, medium and small muscle groups of the upper limbs (ontogeny-oriented kinesiotherapy (OOKT), PNF - proprioceptive neuro-muscle facilitation, training and practice of functional rational self-service tasks). 12 sessions in total were realized 5 times a week and lasted 40 minutes each.
Study: NCT06031259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idursulfase-IT
Description: Idursulfase-IT intrathecally via IDDD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elaprase
Description: Elaprase IV infusion.
Study: NCT05973747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Gluconate
Description: Infused intravenously over 10 minutes upon umbilical cord clamping. First 10 assigned patients received 2 grams per protocol. Subsequent 13 patients received 1.5 grams, dose recalibrated per protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium chloride
Description: 0.5 grams of calcium chloride, infused intravenously over 10 minutes upon umbilical cord clamping
Study: NCT05068973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOVATECH® LUCIOLA™ EB - (Fiducial Marker)
Description: Bronchoscopic implantation in the lung of the NOVATECH® LUCIOLA™ EB fiducial marker
Study: NCT06484777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9539 for injection
Description: SHR-9539 for dose escalation/dose extension
Study: NCT06478004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct composite restoration of carious primary anterior teeth using custom 3D printed templates
Description: A patient dental model is acquired by digital scan then digital waxing-up is performed using the Exocad software to 3D print clear templates for direct composite resin restoration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct composite restoration of carious primary anterior teeth using conventional strip crowns
Description: Direct composite resin restoration using celluloid crown forms
Study: NCT04545515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed dose combination (FDC) tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study: NCT06406127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid 600 MG Oral Capsule
Description: Single 600 mg daily dose
Study: NCT04990895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires
Description: A web-based portal that prompts participants to enter tumour-specific ePROs at regular intervals in between clinic visits
Study: NCT06031571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dry cupping massage
Description: Dry cupping is a form of massage therapy that involves using Hijamat cups without skin injury while applying suction and then performing circular and transverse movements
Study: NCT06037148

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Match DM-101PX
Description: Placebo to match DM-101PX administered subcutaneously
Study: NCT05378568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the selection scheme of peripheral venous access devices
Description: Based on the Facilitator Toolkit of the promoting action on research implementation in health services integrated framework(i-PARIHS), the implementation plan of peripheral intravenous infusion device selection in hospitalized children was formulated and applied, so as to change the practice behavior of nurses in the intervention group. The specific process mainly includes: tailoring evidence; baseline review; situational analysis; promotion and implementation strategy like lectures, group discussions, operation demonstrations, and scenario simulations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the existing nursing routine
Description: To choose infusion device according to nurse's working experience. First, nurse placed a peripheral intravenous catheter. The patients and family decide whether to place the central intravenous infusion device according to the recommendation of the medical staff.
Study: NCT06192407

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oleic Acid Diet
Description: Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is 100% hazelnut oil. They will be taught to consume the oil with each meal and mix it in with the food provided.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Palmitic Acid Diet
Description: Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is palm oil-89%, peanut oil-6.75%, and virgin olive oil-4.25%; . They will be taught to consume the oil with each meal and mix it in with the food provided.
Study: NCT06111794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REACH TBI
Description: Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) is a six-session, telephone intervention for Caregivers of Veterans and Services Members with TBI. The intervention focuses on problem solving training, stress management, and psychoeducation. Trained Program Coaches will deliver the REACH TBI intervention by meeting one-on-one via telephone with participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REACH TBI
Description: Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) is a six-session, telephone intervention for Caregivers of Veterans and Services Members with TBI. The intervention focuses on problem solving training, stress management, and psychoeducation. Trained Program Coaches will deliver the REACH TBI intervention by meeting one-on-one via telephone with participants.
Study: NCT06257511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation-Based Mastery Learning of the Non-technical skills
Description: Participants will participate in a simulation-based mastery learning of the non-technical skills.
Study: NCT06031571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofacial release
Description: Myofascial release is a form of manual therapy using hands-on techniques to regain tissue extensibility and elasticity
Study: NCT04888975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dayspring Active Wearable Compression System
Description: Dayspring Active Wearable Compression System
Study: NCT04737538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Dentrifrice
Description: Toothpaste containing sodium bicarbonate, sodium hyaluronate and sodium fluoride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive control dentifrice
Description: Dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative control dentifrice
Description: Dentifrice containing 1100ppm fluoride as sodium fluoride (Crest Cavity Protection)
Study: NCT06406062

Intervention type: DEVICE
Intervention: ANDOANGEL
Description: Polyps were identified by endoscopists assisted by an AI system: rectangular box marks; Monitoring of ileocecal position: whether blindness was reached was displayed in the lower left corner of the interface.~Mirror entry and exit time monitoring: the operation time is displayed in the upper left corner of the interface.~Colonoscopy withdrawal speed monitoring: the relative withdrawal speed was displayed on the left side of the interface.
Study: NCT05736679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In2Care EaveTube
Description: In2Care® EaveTubes (ETs) comprise 15 cm diameter, 20 cm long ventilation tubes with removable netting inserts that are placed in the wall under the roof of houses where they attract malaria mosquitoes at night, block them from entering the house, and contaminate them with a lethal dose of insecticide. In2Care® ET netting inserts have an electrostatically charged coating treated with bio-actives in powder form, which kills insecticide-resistant mosquitoes through high active ingredient dose transfer.
Study: NCT05545670

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: not containing drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 300 MG
Description: a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
Study: NCT05709171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: PET/CT scan approximately 60 min after injection of 18F-FDG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-Dotatate
Description: PET/CT scan approximately 60 min after injection of 64Cu-Dotatate
Study: NCT05449028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H. pylori eradication scheme A
Description: Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H. pylori eradication scheme B
Description: Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H. pylori eradication scheme C
Description: Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H. pylori eradication scheme D
Description: Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H. pylori eradication scheme E
Description: Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
Study: NCT04518891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy (CFT)
Description: Cognitive functional therapy (CFT) is an intervention that deals with potentially modifiable multidimensional aspects of pain (e.g. provocative cognitive, movement and lifestyle behaviours). Treatment with CFT will be individualised, the physiotherapist will listen to the complete patient pain history and the intervention will be focused on individual needs. A detailed examination will be crucial in identifying the modifiable multidimensional mediators of pain and disability (provocative cognitive, pain, movement and lifestyle behaviors) of each participant.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: Due to the impossibility of applying placebo exercise, the control intervention in this study will be based on successful reports of placebo intervention in patients with chronic low back pain in the literature (Placebo photobiomodulation + neutral talking control)
Study: NCT06469008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B16D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06481059

Intervention type: RADIATION
Intervention: Head and Neck cancer post-radiotherapy
Description: Head and Neck Cancer patients who received radiotherapy after 6 months